Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) reached a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $11.68 and last traded at $11.75, with a volume of 169623 shares. The stock had previously closed at $11.22.
Analyst Upgrades and Downgrades
A number of research analysts have recently commented on the stock. Barclays boosted their price target on shares of Alpha Tau Medical from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, June 4th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alpha Tau Medical in a research report on Monday, April 20th. LADENBURG THALM/SH SH lifted their price objective on Alpha Tau Medical from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, May 12th. Piper Sandler boosted their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 19th. Finally, HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of Alpha Tau Medical in a research report on Tuesday, June 2nd. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Alpha Tau Medical presently has an average rating of “Hold” and a consensus price target of $12.60.
Get Our Latest Stock Report on DRTS
Alpha Tau Medical Stock Performance
Alpha Tau Medical (NASDAQ:DRTS – Get Free Report) last announced its earnings results on Monday, May 18th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.13). Equities analysts anticipate that Alpha Tau Medical Ltd. will post -0.67 earnings per share for the current fiscal year.
Insider Activity
In other news, CFO Raphi Levy sold 20,000 shares of Alpha Tau Medical stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $11.00, for a total transaction of $220,000.00. Following the completion of the sale, the chief financial officer directly owned 110,180 shares of the company’s stock, valued at approximately $1,211,980. The trade was a 15.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 70,000 shares of company stock worth $739,100. Insiders own 39.50% of the company’s stock.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in the company. Trifecta Capital Advisors LLC bought a new stake in Alpha Tau Medical during the fourth quarter worth about $48,000. Envestnet Asset Management Inc. purchased a new position in shares of Alpha Tau Medical in the 3rd quarter worth about $62,000. Bank of America Corp DE increased its position in shares of Alpha Tau Medical by 2,779.1% during the 3rd quarter. Bank of America Corp DE now owns 22,457 shares of the company’s stock valued at $101,000 after purchasing an additional 21,677 shares during the last quarter. Wells Fargo & Company MN increased its position in shares of Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock valued at $116,000 after purchasing an additional 17,500 shares during the last quarter. Finally, Principal Financial Group Inc. purchased a new position in shares of Alpha Tau Medical during the 1st quarter valued at about $132,000. Institutional investors own 2.65% of the company’s stock.
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Featured Stories
- Five stocks we like better than Alpha Tau Medical
- Volkswagen’s 16-Year Low Masks a Massive Margin Engine
- Palantir’s Rough 2026 Start Raises a Bigger Question About Its AI Moat
- Manchester United’s Stock Rally Faces a Test Beyond Old Trafford
- Overclocking Qualcomm: Rewiring the AI Compute Market
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
